This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Freeline Therapeutics Holdings Résultats passés
Passé contrôle des critères 0/6
Freeline Therapeutics Holdings's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 112.4% per year.
Informations clés
-6.3%
Taux de croissance des bénéfices
43.9%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 112.4% |
| Rendement des fonds propres | -166.2% |
| Marge nette | -8,027.7% |
| Dernière mise à jour des bénéfices | 30 Sep 2023 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Ventilation des recettes et des dépenses
Comment Freeline Therapeutics Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -50 | 32 | 34 |
| 30 Jun 23 | 1 | -53 | 40 | 37 |
| 31 Mar 23 | 0 | -61 | 39 | 47 |
| 31 Dec 22 | 0 | -89 | 42 | 53 |
| 30 Sep 22 | 0 | -101 | 43 | 66 |
| 30 Jun 22 | 0 | -117 | 41 | 80 |
| 31 Mar 22 | 0 | -132 | 46 | 86 |
| 31 Dec 21 | 0 | -140 | 45 | 93 |
| 30 Sep 21 | 0 | -144 | 49 | 86 |
| 30 Jun 21 | 0 | -138 | 39 | 85 |
| 31 Mar 21 | 0 | -115 | 33 | 70 |
| 31 Dec 20 | 0 | -96 | 26 | 61 |
| 30 Sep 20 | 0 | -73 | 20 | 53 |
| 30 Jun 20 | 0 | -63 | 22 | 40 |
| 31 Mar 20 | 0 | -58 | 17 | 41 |
| 31 Dec 19 | 0 | -54 | 17 | 36 |
| 31 Dec 18 | 0 | -33 | 7 | 26 |
| 30 Sep 17 | 0 | -17 | 7 | 11 |
Des revenus de qualité: FRLN is currently unprofitable.
Augmentation de la marge bénéficiaire: FRLN is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: FRLN is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accélération de la croissance: Unable to compare FRLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: FRLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Rendement des fonds propres
ROE élevé: FRLN has a negative Return on Equity (-166.22%), as it is currently unprofitable.